EcoDrugPlus

Glutamate Receptor, Metabotropic 3

Ensembl ID : ENSOJAG00000004476
Gene Symbol: GRM3
1 Cross references
215 Possible Orthologues:

Glutamate Receptor, Metabotropic 5a

Ensembl ID : ENSOJAG00000008937
Gene Symbol: GRM5A
1 Cross references
211 Possible Orthologues:

Glutamate Receptor, Metabotropic 5b

Ensembl ID : ENSOJAG00000008315
Gene Symbol: GRM5B
1 Cross references
214 Possible Orthologues:

Glutaminase A

Ensembl ID : ENSOJAG00000003293
Gene Symbol: GLSA
1 Cross references
230 Possible Orthologues:

Glycogen Synthase Kinase 3 Alpha A

Ensembl ID : ENSOJAG00000017982
Gene Symbol: GSK3AA
1 Cross references
187 Possible Orthologues:

Glycogen Synthase Kinase 3 Alpha B

Ensembl ID : ENSOJAG00000019454
Gene Symbol: GSK3AB
1 Cross references
186 Possible Orthologues:

Glycogen Synthase Kinase 3 Beta, Genome Duplicate A

Ensembl ID : ENSOJAG00000008148
Gene Symbol: GSK3BA
1 Cross references
222 Possible Orthologues:

Growth Hormone Secretagogue Receptor A

Ensembl ID : ENSOJAG00000008643
Gene Symbol: GHSRA
1 Cross references
212 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Alpha 1

Ensembl ID : ENSOJAG00000006979
Gene Symbol: GUCY1A1
1 Cross references
201 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Alpha 2

Ensembl ID : ENSOJAG00000016063
Gene Symbol: GUCY1A2
1 Cross references
202 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Beta 1

Ensembl ID : ENSOJAG00000006885
Gene Symbol: GUCY1B1
1 Cross references
209 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Beta 1

Ensembl ID : ENSOJAG00000011865
Gene Symbol: GUCY1B1
1 Cross references
209 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).